Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $163 thousand versus the consensus estimate of $58.75 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.